Fenwal, which offers a wide range of products for the automated and manual collection, filtration, separation, storage and transfusion of blood and its components, has received CE mark for a therapeutic plasma exchange (TPE) protocol for company’s cell separation system Amicus.
Fenwal’s Amicus system is used to collect platelets, platelets with concurrent plasma and red cells, and mononuclear cells used for therapeutic applications and clinical research.
The continuous-flow TPE procedure on the Amicus system is designed to be efficient with minimal operator intervention.
The Amicus system with TPE uses a disposable collection set to draw blood from patients for automatic, chair-side separation to remove the plasma containing harmful substances, and return to the patient his or her own red cells, platelets and a plasma-replacement solution made up saline, human albumin and other components.
Fenwal chief technology officer William Cork said the Amicus system with platelet and mononuclear cell collection, and now with TPE, offers medical professionals a solution for helping to treat hematologic, neurologic, autoimmune, and kidney disorders.
"We continue to expand our offerings in blood technologies to help make blood therapies to create value for blood centers, hospitals and other sites of care," Cork said.